Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 25 of 37, showing 5 Applications out of 183 total, starting on record 121, ending on 125

# Protocol No Study Title Investigator(s) & Site(s)

121.

ECCT/24/05/06   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) - Kisumu (Kisumu county)
 
View

122.

ECCT/24/06/01   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Raymond Scott McClelland
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
 
View

123.

ECCT/24/06/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Charity Wambui Kanyoro
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

124.

ECCT/24/07/05   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Bernhards Ogutu
Site(s) in Kenya
1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county)
 
View

125.

ECCT/24/10/02   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county)
 
View